The advent of engineered immune cell therapies targeting malignant cells has transformed the landscape of cancer treatment. However, the clinical experience to date has indicated a number of barriers to the broad applicability of existing patient- and donor-derived cell-based cancer immunotherapy approaches such as CD19-targeting CAR-T cells. The use of a clonal master engineered induced pluripotent stem cell (iPSC) line as a renewable source for the mass production of immune cells offers distinct advantages that address these common barriers, including off-the-shelf availability for broad access to patients and multi-dose administration of homogenous engineered cell products with consistent identity, purity, and potency. In this talk, Dr. Wayne Chu, Senior Vice President of Clinical Development at Fate Therapeutics shares recent clinical data from the company’s off-the-shelf iPSC-derived NK cell therapies for the treatment of hematologic malignancies, including acute myeloid leukemia and B-cell lymphoma. The clinical evidence demonstrates the potential of iPSC-derived NK cell therapies in that they can be consistently administered in multiple doses, are safe and tolerable, and can generate clinically meaningful activity in patients with relapsed/refractory disease.

_Presenter:

Wayne Chu, M.D.

_{Senior Vice President, Clinical Development @ Fate Therapeutics}

_{Dr. Yu-Waye (Wayne) Chu is Senior Vice President, Clinical Development at Fate Therapeutics, overseeing the company’s clinical development strategies. Prior to joining Fate, Wayne assumed roles of increasing responsibility in Product Development Oncology at Genentech since 2009, where he worked on the development of the HER2-directed antibody drug conjugate trastuzumab emtansine (Kadcyla). He joined the Early Clinical Development group in Genentech Research and Early Development (gRED) in 2011 where he led the early clinical development of molecules spanning multiple therapeutic platforms including antibody drug conjugates, checkpoint inhibitors, and immune cell bispecific antibodies, notably the development of polatuzumab vedotin (anti-CD79b antibody drug conjugate), tiragolumab (anti-TIGIT monoclonal antibody) and mosunetuzumab (CD20/CD3 bispecific antibody), and continued to lead the global development of mosunetuzumab in Product Development Oncology at Roche/Genentech. Dr. Chu conducted his clinical training in pediatric hematology-oncology at Johns Hopkins School of Medicine and the National Cancer Institute. His major clinical and research interests included hematopoietic stem cell transplantation for the treatment of pediatric cancers, and T-cell biology with a focus on T-cell development and maturation, T-cell homeostasis and immune reconstitution following stem cell transplant. Dr. Chu graduated cum laude with a B.A. in Molecular Biology from Princeton University, and earned his M.D. with Distinction in Research from the University of Rochester School of Medicine and Dentistry.}